Patent US5846773A successfully refreshed from Google Patents.
US5846773A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Single gene encoding aortic-specific and striated-specific muscle cell isoforms and uses thereof
Assignee: Harvard University
•
Filing: 1997-02-06
•
Granted: 1998-12-08
•
Expires: 2017-02-06
Abstract
Abstract Aortic-preferentially-expressed gene-1 (APEG-1) and striated muscle preferentially expressed (SPEG) polypeptide, DNA sequences encoding and controlling the transcription of the APEG-1/SPEG encoding gene, methods of diagnosing vascular injury, methods of conferring smooth muscle-cell specific expression, and methods of inhibiting vascular smooth muscle cell proliferation by increasing the level of APEG-1 at the site of vascular injury.
Inventors
- 👤 Mu-En Lee
- 👤 Chung-Ming Hsieh
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 19:46
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4716; A; A61; A61K; A61K38/00; A61K48/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
31 words
A substantially pure DNA comprising an APEG-1 promoter/enhancer sequence, wherein said promoter/enhancer sequence is operably linked to a polypeptide-encoding sequence and regulates vascular smooth muscle cell-specific transcription of said polypeptide-encoding sequence.
Claim 2
Dependent Claim
31 words
A substantially pure DNA comprising an APEG-1 promoter/enhancer sequence, wherein said promoter/enhancer sequence is operably linked to a polypeptide-encoding sequence and regulates vascular smooth muscle cell-specific transcription of said polypeptide-encoding sequence.
Claim 3
Dependent Claim
13 words
The DNA of claim 1, wherein said promoter/enhancer sequence comprises SEQ ID NO:17.
Claim 4
Dependent Claim
17 words
The DNA of claim 1, wherein said promoter/enhancer sequence regulates developmental stage-specific expression of said polypeptide-encoding sequence.
Claim 5
Dependent Claim
13 words
The DNA of claim 1, wherein said polypeptide-encoding sequence does not encode APEG-1.
Claim 6
Dependent Claim
8 words
A vector comprising the DNA of claim 4.
Claim 7
Dependent Claim
30 words
A method of directing vascular smooth muscle cell-specific expression of a polypeptide, comprising introducing into a vascular smooth muscle cell the vector of claim 5; and expressing the polypeptide-encoding sequence.
Claim 8
Dependent Claim
28 words
A method of directing developmental stage-specific expression of a polypeptide, comprising introducing into a vascular smooth muscle cell the vector of claim 5; and expressing the polypeptide-encoding sequence.
Claim 9
Dependent Claim
30 words
The DNA of claim 1, wherein said polypeptide is chosen from the group consisting of tissue plasminogen activator, p21 cell cycle inhibitor, nitric oxide synthase, interferon-γ, and atrial natriuretic polypeptide.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-12-07 | 2002-06-08 | 2002-12-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-12-07 | 2006-06-08 | 2006-12-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-12-07 | 2010-06-08 | 2010-12-08 | $7700.00 | Window Closed / Lapsed |